ç—tŒ§–òÜŽt‰ï@–òŽ–î•ñƒZƒ“ƒ^[
˜_•¶“™
¨Šw‰ï”­•\“™
1. Œ´’˜˜_•¶
E ”Ñ“ˆ‹vŽu, ˜h”ö–². Bradford‚Ì–@‘¥‚ÉŠî‚­ƒRƒAEƒWƒƒ[ƒiƒ‹‚Ì‘I’è‚Æ•]‰¿ `Á‰»«’×ᇎ¡—Öò‚ð‘ΏۂƂµ‚ā`.
@ˆã–ò•iî•ñŠw 2021; 23 (1): 26-31.
Eª–{ ˆ¨, ”Ñ“ˆ‹vŽu, ™‰Y–M•v, ¬²–ìˆè, ìè—TŽq, Žá—Ñ i, oÎŒ[Ž¡, ‹{è’·ˆê˜Y, ‹{ú±—œ¨, ¼àV ”E, ªŠÝŒ’ˆê,
@Ž­‘ºŒb–¾. @OTCˆã@–ò•i‚Ì•›ì—p•ñ„i‚ÉŒü‚¯‚½Œ[”­Ž‘Þ‚ÌŠJ”­‚Æ•]‰¿. ˆã–ò•iˆÀ‘SŠw2020; 6: 9-18.
EHisashi Iijima, Miwako Kamei. Trends in Study Design Assessment for Anti-Influenza Agents. Japanese
@Journal of Pharmaceutical @Health Care and Sciences 2019; 45 (8): 451-459.
EHisashi Iijima, Miwako Kamei. Longitudinal Evaluation and Meta-analysis of Clinical Articles on the
@Antihypertensive@Effects of@Incretin-related Drugs. Japanese Journal of Pharmaceutical Health Care
@and Sciences 2017; 43 (4): 201-214.
E”Ñ“ˆ‹vŽu, ‘吟•ü. ƒƒ^ƒAƒiƒŠƒVƒX˜_•¶‚É‚¨‚¯‚é•]‰¿Šî€‚̑Ó–«‚ƃf[ƒ^’Šo@`ƒCƒ“ƒNƒŒƒ`ƒ“ŠÖ˜A–ò‚ÌŽ¡—ÃŒø‰Ê
@‚Æ•›ì—p`. ˆã–ò•iî•ñŠw 2016; 18 (1): 22-32.
E”Ñ“ˆ‹vŽu, Î–ì—ǘa. –ò‹Ç‚É‚¨‚¯‚éˆã—Ïî•ñŒ¹‚Æ’²Ü‹@Ší‚ÌŒ»ó‚Ɖۑè@`ç—tŒ§‚É‚¨‚¯‚é‰ß‹Ž‚Ì’²¸Œ‹‰Ê‚𓥂܂¦‚ā`
@ˆã—ÖòŠw 2015; 41 (10): 705-713.
E”Ñ“ˆ‹vŽu, ‰F–ìO“W, ‘吟•ü, K“c^ƒ, 趉ꋧŽj, ‘å–ØŒ’Žj, ‘å’ˏ~ˆê, –Ø‘º‘Žq, ‹ß“¡ ’‰, ’Å–¼—Yˆê, ’·àVG”V, –qŽR
@‘׎m, ÂŽR—²•v, ¬“ˆ•¶—Ç, ¬–Γc¹‘ã, “úûüT“ñ, –öì’‰“ñ, ÎˆäˆÉ“sŽq, ž¥ ‘¥–¾, …–ì –Î. –ò‹Ç‚É‚¨‚¯‚é’²Ü•û–@‚Ì‘Š
@ˆá‚Æ–â‘è“_. ç—tŒ§–òÜŽt‰ïŽGŽ2016; 62 (2): 77-81.
E”Ñ“ˆ‹vŽu, ‘吟•ü. “à—e•ªÍ‚ÉŠî‚­˜AŒgƒtƒH[ƒ}ƒbƒg‚̍쐬. “ú–{ˆã—Ã}ƒlƒWƒƒ“ƒgŠw‰ïŽGŽ 2015; 15 (4): 242-246.
E”Ñ“ˆ‹vŽu, K“c^ƒ, ã‘º‹v”üŽq, ìŸŒö”üŽq, •–ØŒõ—Ç, ‚‹´áÁ¶, ¼“‡³Œ›, ´…Ž•F, à_“cŒå. “dŽq–ò—ð‚ð—˜—p‚µ‚½
@î•ñ‹¤—L•¶‘ì¬ƒVƒXƒeƒ€‚̍\’z‚Æ•]‰¿. ˆã—Ïî•ñŠw 2013; 33 (3): 161-169.
ETomoka Osumi, Hisashi Iijima. Assessment and Analysis of the Assessment Criteria for Meta-Analysis Articles
@- Management of Diabetes Pharmacotherapy Based on Meta-Analysis Articles -. Japanese Journal of Pharmaceutical
@Health Care and Sciences 2013. 39. 347-355.
EÂ–ìŽj, ¬“¡‚ ‚¸‚³, –öŒ´ç‰ê, —À£‰ÁŽõŽq, ”Ñ“ˆ‹vŽu, ¬–Γc¹‘ã. •½¬19”NA•½¬23”N‚Ì”äŠr‚©‚猩‚½—Տ°Œ¤‹†‚ÉŠÖ
@‚·‚é’²¸@|—Ï—R¸ˆÏˆõ‰ï®”õó‹µ‚Æ–òÜŽt‚ÌŽQ‰æ‚ւ̉ۑè|. ç—tŒ§–òÜŽt‰ïŽGŽ2014. 60 (2): 71-77.
EÂŽR—²•v, â—œ•üŽq, Ô–Ø—S‹M, ”Ñ“ˆ‹vŽu, Î–ì—ǘa. •ÛŒ¯–ò‹Ç‚É‚¨‚¯‚鐻Ü‹Æ–±‚ÌŽÀ‘Ô’²¸‚Æ–â‘è“_‚̉ðÍ.
@ç—tŒ§–òÜŽt‰ïŽGŽ 2012. 55 (4): 278-284.
E”Ñ“ˆ‹vŽu, ŸN“c‘å–ç, ‘吟•ü, –ƒ¶’‰’j, ²“¡M”Í. ˆ•û‚¹‚ñ‹LÚ•û–@‚ÉŠÖ‚·‚é’²¸‚ƍ¡Œã‚̑Ήž.
@ç—tŒ§–òÜŽt‰ïŽGŽ2012. 58 (3): 171-174.
E‘吟•ü, ”Ñ“ˆ‹vŽu. —Տ°˜_•¶‚ÉŠî‚­RƒCƒ“ƒtƒ‹ƒGƒ“ƒU–ò‚Ì‹qŠÏ“I•]‰¿.
@Clinical Pharmacist 2011; 3 (4): 389-394.
E”Ñ“ˆ‹vŽu, ‘吟•ü, ¬´…•q¹. ƒƒ^ƒAƒiƒŠƒVƒX˜_•¶‚É‚¨‚¯‚é•]‰¿Šî€‚̍쐬‚Æ•ªÍ `“œ”A•a‚ƃŒƒjƒ“EƒAƒ“ƒWƒIƒe
@ƒ“ƒVƒ“Œn‘jŠQ–ò‚ÌŠÖ˜A`. –òŠwŽGŽ 2010; 130 (9): 1215-1223.
E”Ñ“ˆ‹vŽu, ‘吟•ü. ’nˆæˆã—ØAŒg‚É•K—v‚È•ž–òŠÇ—î•ñ‚̃xƒNƒgƒ‹•ªÍ. ˆã—Ïî•ñŠw 2009; 29 (Suppl.): 483-485.
E”Ñ“ˆ‹vŽu, ‰F–ìO“W, ‘åÎŒ›Ži, –Ø‘º_“ñ, ¼‹´—R‹IŽq, Ž›“àM•v, ¼‰ª’¼l, “c”¨‹`O, ‹gì´Žj, •ìTŒá, Î–ì—ǘa.
@–ò‹Ç•ÛŒ¯¿‹ƒVƒXƒeƒ€‚É‚æ‚éŒg‘Ñ“d˜b‚ւ̏î•ñ’ñ‹ŸƒVƒXƒeƒ€‚̍\’z. ˆã—Ïî•ñŠw 2008; 28 (1): 31-37.
EˆäŽèŽá“Þ, ”Ñ“ˆ‹vŽu, ‰F–ìO“W, –Ø‘º‰pW, ‹v•Û“c—mŽq, àV“cˆ¤Žq, •½ˆä­•F, ‹gì^—R”ü, —é–Ø‹v•v, Î–ì—ǘa, ˆÀ“¡G
@l. @Bisphosphonate»Ü‚¨‚æ‚ÑRaloxifene‚̃Rƒ“ƒvƒ‰ƒCƒAƒ“ƒX‚È‚ç‚Ñ‚É—LŠQŽ–Û’²¸ (ç—tŒ§”ÅDEM).
@ˆã—ÖòŠw 2008; 34 (5): 455-460.
E”Ñ“ˆ‹vŽu, ˆäŽèŽá“Þ, ‰F–ìO“W, –Ø‘º‰pW, ‹v•Û“c—mŽq, ‘ò“cˆ¤Žq, —é–Ø‹v•v, •½ˆä­•F, ‹gì^—R”ü, Î–ì—ǘa, ˆÀ“¡G
@l. ç—tŒ§‚Ì–ò‹Ç‚É‚¨‚¯‚é–òÜî•ñ’ñ‹Ÿ•¶‘‚̏‘Ž®‚Əî•ñ’ñ‹Ÿ‚ÉŠÖ‚·‚é’²¸. ˆã—Ïî•ñŠw 2007; 27 (4): 387-392.
EHisashi Iijima, Hironobu Uno, Wakana Ide, Aiko Sawata, Hisao Suzuki, Masahiko Hirai, Yoshikazu Ishino,
@Hideto Ando. An Analysis of Recovery Time from Influenza Symptoms and Side Effects Based on Patient-Recorded
@Oseltamivir Treatment. Japanese Journal of Drug Informatics 2007; 9 (1): 53-57.
E”Ñ“ˆ‹vŽu, ŸNˆä³‘¾˜Y, ¬–Γc¹‘ã. ˆã—Ë@ŠÖ‚É‚¨‚¯‚é’²Ü•û–@‚Ì‘Šˆá‚Æ–â‘è“_.
@“ú–{•a‰@–òÜŽt‰ïŽGŽ2007; 43 (6): 785-789.
E”Ñ“ˆ‹vŽu, ¬´…•q¹, ”’_½. ƒWƒFƒlƒŠƒbƒNˆã–ò•i‚É‚¨‚¯‚é“ÆŽ©î•ñ‚Ì‹qŠÏ“I•]‰¿.
@–òŠwŽGŽ 2007; 127 (3): 541-545.
E‰F–ìO“W, ”Ñ“ˆ‹vŽu. –ò‹Ç‚É‚¨‚¯‚é—Տ°ŒŸ¸’l‚Ì“üŽèó‹µ‚Æ‚»‚Ì•K—v«. ˆã–ò•iî•ñŠw 2007; 8 (4): 302-306.
E”Ñ“ˆ‹vŽu, Îˆä¹G, ‹àe ”£, ì“‡ˆê•v, –Ø‘º˜aŽi, ¬Žº—T•Û, Ä“¡ Š°, ‚‹´t•v, ”¨’†”ÍŽq, –ö“c˜a—Ç, —RˆäGˆê, –îè
@œA‹v, “¡‘ã—Ç•F, ŒÃŽR—zˆê, •ÄàV³–¾. Ticlopidine Hydrochlorideù‚É‚¨‚¯‚éŒã”­ˆã–ò•i‚Ì•iŽ¿•]‰¿.
@ç—tŒ§–òÜŽt‰ïŽGŽ2007; 53 (3): 183-185.
E”Ñ“ˆ‹vŽu, ŽR–숟ŠóŽq, ¬´…•q¹, ”’_½. Thalidomide •¶Œ£î•ñ‚Ì•Ï“®‚Ì•ªÍ.
@ˆã–ò•iî•ñŠw 2006; 7 (4): 300-305.
E”Ñ“ˆ‹vŽu, Ä“¡D•x, •ÄàV³–¾, –ΖؔŽ. ç—tŒ§‚É‚¨‚¯‚é–Ê•ª‹Æ„ió‹µ‚Ì’²¸‚Æ–ò‹Ç‹Æ–±‚̉ü‘P‚ÉŒü‚¯‚½•ûô.
@ˆã—ÖòŠw 2005; 31 (11): 931-935.
E‰F–ìO“W, ”Ñ“ˆ‹vŽu, ˆ°“cNs, ˆäŽèŽáØ, ‹v•Û“c—mŽq, àV“cˆ¤Žq, Î–ì—ǘa, ˆÀ“¡Gl. –ò‹Ç‚É‚¨‚¯‚éŒg‘у[ƒ‹‚ð—˜—p
@‚µ‚½ˆã–ò•iî•ñ’ñ‹Ÿ. ˆã–ò•iî•ñŠw 2005; 7 (3): 204-207.
E”Ñ“ˆ‹vŽu, ‹Tˆä”ü˜aŽq, ¬´…•q¹, ”’_½. ƒWƒFƒlƒŠƒbƒNˆã–ò•i‚É‚¨‚¯‚éd—v“x‚¨‚æ‚Ñ•K—v“xŒW”‚ÉŠî‚­î•ñ•]‰¿.
@–òŠwŽGŽ 2005; 125 (9): 739-747.
E”Ñ“ˆ‹vŽu, Î–ì—ǘa, ˆÀ“¡Gl, –ΖؔŽ. –ò‹Ç‚É‚¨‚¯‚銳ŽÒî•ñ‚Ì“üŽè•û–@‚ÆŠˆ—p‚ÉŠÖ‚·‚é’²¸.
@ˆã—ÖòŠw 2005; 31 (3): 223-227.
E”Ñ“ˆ‹vŽu, ˆäŽèŽá“Þ, ‰F–ìO“W, ‹v•Û“c—mŽq, ‘ò“cˆ¤Žq, “c’†–õË, Î–ì—ǘa. –ò‹Ç‚É‚¨‚¯‚é—L—p‚Ȉã–ò•iî•ñŒ¹‚Æ‚»‚Ì–â
@‘è“_. ˆã–ò•iî•ñŠw 2005; 6 (4): 263-267.
EHisashi Iijima, Miwako Kamei, ToshimasaKoshimizu, Makoto Shiragami. Objective Evaluation of Generic
@Drug Information. YAKUGAKU ZASSHI 2004; 124 (6): 341-347.
E”Ñ“ˆ‹vŽu, ‹Tˆä”ü˜aŽq, ¬´…•q¹, ”’_½. HMG-CoAŠÒŒ³y‘f‘jŠQÜ‚É‚¨‚¯‚éƒWƒFƒlƒŠƒbƒNˆã–ò•i‚̏î•ñ—Ê‚Ì•]‰¿.
@ˆã—ÖòŠw 2004; 30 (3): 173-179.
E”Ñ“ˆ‹vŽu, •èÆ‘ã, ‹Tˆä”ü˜aŽq, ¬´…•q¹, ”’_½. ˆã—Ë@ŠÖˆã–ò•iî•ñŽº‚É‚¨‚¯‚éˆã–ò•iî•ñŒ¹‚ÌŒ»ó.
@ˆã–ò•iî•ñŠw 2004; 5 (4): 213-217.
EHisashi Iijima, Teruyo Kurosaki, Miwako Kamei, ToshimasaKoshimizu, Makoto Shiragami. Valuing the Drug
@Information Provided for Generics in Setting the Price of Generic Drugs in Japan.
@Drug Information Journal 2004; 38 (3): 265-272.
E”Ñ“ˆ‹vŽu, ‹ù•ûˆºŽq, ˆäŒû–@’j. –òŠw•”2”NŽŸ‚É‚¨‚¯‚é–ò‹ÇŒ©ŠwŽÀK‚Æ‚»‚̈Ӌ`. ˆã—ÖòŠw 2003; 29 (6): 732-739.
E”Ñ“ˆ‹vŽu, •èÆ‘ã, ‹Tˆä”ü˜aŽq, ¬´…•q¹, ”’_½. ƒWƒFƒlƒŠƒbƒNˆã–ò•i‚É‚¨‚¯‚éî•ñ•]‰¿‚Ì•K—v“xŒW”ŽZo.
@–òŠwŽGŽ 2003; 123 (12): 1039-1047.
E”Ñ“ˆ‹vŽu, Î–ì—ǘa, ˆÀ“¡Gl, –ΖؔŽ. ˆê”Ê—pˆã–ò•i‚ÉŠÖ‚·‚é–òÜŽt‚̈ӎ¯’²¸.
@ˆã–ò•iî•ñŠw 2003; 5 (3): 187-192.
E”Ñ“ˆ‹vŽu, ˆÀ“¡Gl, ˆäˆÉ³–¤, ˆÉ“¡‹Ï, Îˆäˆêº. ç—tŒ§–òÜŽt‰ï‰ïˆõ–ò‹Ç‚É‚¨‚¯‚éˆã–ò•iî•ñŒ¹‚Æ‚¨–òŽè’ ‚ÌŠˆ—p‚É
@ŠÖ‚·‚é’²¸. ˆã—ÖòŠw 2003; 29 (4): 544-551.
E”Ñ“ˆ‹vŽu, ¬´…•q¹. ƒWƒFƒlƒŠƒbƒNˆã–ò•i‚̈ã–ò•iî•ñ‚Æ–ò‰¿‚ðŠÏ“_‚Æ‚µ‚½‰¿’l•]‰¿.
@ˆã–ò•iî•ñŠw2002; 4 (1): 21-26.
E”Ñ“ˆ‹vŽu, ˆÀ“¡Gl, ˆÉ“¡‹Ï, Îˆäˆêº. ç—tŒ§–òÜŽt‰ï‚É‚¨‚¯‚é“dŽq”}‘Ì‚ð—˜—p‚µ‚½–òŽ–î•ñ’ñ‹Ÿ‚ÆŽûW.
@ˆã–òƒWƒƒ[ƒiƒ‹ 2002; 38 (4): 1293-1297.
E”Ñ“ˆ‹vŽu, ¬´…•q¹, ^–؏ƒˆê. ç—tŒ§‚É‚¨‚¯‚é–ò-–ò˜AŒg‚ÌŒ»ó‚ƍ¡Œã‚Ì“W–].
@ˆã–òƒWƒƒ[ƒiƒ‹ 2001; 37 (10): 3047-3052.

2. ‚»‚Ì‘¼˜_•¶A‘Ð“™
E”Ñ“ˆ‹vŽu. Œ¤‹†ƒvƒ‰ƒ“‚Ì‘g‚Ý—§‚Ä•û‚ÆŽÀŽ{. ’²Ü‚Əî•ñ2020; 26 (7): 1378-1383.
E”Ñ“ˆ‹vŽu. R‚Ä‚ñ‚©‚ñÜ ƒ‰ƒRƒTƒ~ƒh‚̐¸__ŒoŒn‚Ì•›ì—p‚ɂ‚¢‚Ä‚Ì“Y•t•¶‘‚̉ü’ù.
@“ú–{–òÜŽt‰ïŽGŽ 2020; 72 (8): 911-913.
E”Ñ“ˆ‹vŽu. ¶–ò ƒTƒ“ƒVƒV‚Ì’°ŠÔ–ŒÃ–¬d‰»Ç‚Ì•›ì—p‚ɂ‚¢‚Ä‚Ì“Y•t•¶‘‚̉ü’ù.
@“ú–{–òÜŽt‰ïŽGŽ 2019; 71: 383-385.
E”Ñ“ˆ‹vŽu. ŠÉ‰ºÜ ƒZƒ“ƒmƒVƒh‚Ì‘å’°ƒƒ‰ƒm[ƒVƒX‚ɂ‚¢‚Ä‚Ì“Y•t•¶‘‚̉ü’ù.
@“ú–{–òÜŽt‰ïŽGŽ 2019; 71 (3): 389-390.
E”Ñ“ˆ‹vŽuAŽŒ´~A“à“c’¼Ž÷A_—¢ÊŽqA²“¡ˆ¤”ü. ’´ŠÈ’P!! Œ¤‹†—Ï—R¸‚Ɛ\¿`“K³‚ȗՏ°E‰uŠwŒ¤‹†‚̐„i‚ÉŒü
@‚¯‚ā`. “Œ‹ž. –òŽ–“ú•ñŽÐ. 2018.
E”Ñ“ˆ‹vŽu. RRSƒEƒCƒ‹ƒXƒqƒg‰»ƒ‚ƒmƒNƒ[ƒiƒ‹R‘̐»Ü ƒpƒŠƒrƒYƒ}ƒuiˆâ“`Žq‘gŠ·‚¦j‚ÌŒŒ¬”ÂŒ¸­‚Ì•›ì—p‚ɂ‚¢
@‚Ä‚Ì“Y•t•¶‘‚̉ü’ù@“ú–{–òÜŽt‰ïŽGŽ 2018; 70 (7): 954-956.
E”Ñ“ˆ‹vŽu. OTCˆã–ò•i‚ƈã–ò•iî•ñ. “s–òŽGŽ. “Œ‹ž“s–òÜŽt‰ï 2018; 40 (5): 36-40.
E“ú–{–òÜŽt‰ï —Տ°E‰uŠwŒ¤‹†„iˆÏˆõ‰ï. Œ¤‹†—Ï—R¸\¿€”õƒKƒCƒh. 2018
E”Ñ“ˆ‹vŽu. RƒAƒŒƒ‹ƒM[«ŠÉ˜a¸_ˆÀ’èÜ ƒqƒhƒƒLƒVƒWƒ“‰–Ž_‰–AƒqƒhƒƒLƒVƒWƒ“ƒpƒ‚Ž_‰–‚Ì‹}«”Ä”­«”­]«”^áv
@Ç‚ɂ‚¢‚Ä‚Ì“Y•t•¶‘‚̉ü’ù. “ú–{–òÜŽt‰ïŽGŽ 2018; 70 (4): 525-527.
E”Ñ“ˆ‹vŽu. –Ɖu—}§Ü ƒ~ƒRƒtƒFƒm[ƒ‹Ž_ƒ‚ƒtƒFƒ`ƒ‹‚̍ÊïŒ`«‚ɂ‚¢‚Ä‚Ì“Y•t•¶‘‚̉ü’ù.
@“ú–{–òÜŽt‰ïŽGŽ 2017; 69 (7): 923-925.
E”Ñ“ˆ‹vŽu. ‘I‘ð“ISGLT2‘jŠQÜ‚Ì”sŒŒÇ‚Ì•›ì—p‚ɂ‚¢‚Ä‚Ì“Y•t•¶‘‚̉ü’ù.
@“ú–{–òÜŽt‰ïŽGŽ 2017; 69 (3): 351-356.
EŽR‰YŽ“T, —é–Ø ‹§, ‹Tˆä”ü˜aŽq, ŒF’J—YŽ¡, ˆÉ¨—Y–ç, ŽR–{hŽi, ”Ñ“ˆ‹vŽu. ’´ŠÈ’P! ! ˜_•¶ì¬ƒKƒCƒh `uŒ¤‹†v‚µ‚æ
@‚¤`. “Œ‹ž. –òŽ–“ú•ñŽÐ. 2016.
E”Ñ“ˆ‹vŽu, ˆÉ“¡”ü»Žq, ‘å–ìK•v, –ؐì”ü”T—¢, K“c^ƒ, ‚‹´Œ›“ñ, ‚‹´áÁ¶, ‚–ö˜_–ç, –{àV—t—¯”ü, áÁ“ç’mŽj, “n•”^
@²”ü. ç—tŒ§‹¤—p’nˆæˆã—ØAŒgƒpƒX–òÜƒV[ƒg‚É‚¨‚¯‚éProblem’Šo‚ÉŒü‚¯‚½‰Û‘è.
@“ú–{POSˆã—Êw‰ïŽGŽ 2016; 20 (1). 145-148.
E”Ñ“ˆ‹vŽu. ‘I‘ð“IDPP-4‘jŠQÜ ƒVƒ^ƒOƒŠƒvƒ`ƒ“ƒŠƒ“Ž_‰–…˜a•¨‚ÌRS3PEÇŒóŒQ‚Ì•›ì—p‚ɂ‚¢‚Ä‚Ì“Y•t•¶‘‚̉ü’ù.
@“ú–{–òÜŽt‰ïŽGŽ 2016; 68 (5): 907-910.
E”Ñ“ˆ‹vŽu. ”DPŽž‚ÉŒoŒûƒXƒeƒƒCƒh‚ð•ÏX‚·‚闝—R. “úŒoDI. 2015; (11) 035-036.
E”Ñ“ˆ‹vŽu. ŒoŒûFXa‘jŠQÜ ƒAƒsƒLƒTƒoƒ“‚ÌŠÔŽ¿«”xŽ¾Š³‚Ì•›ì—p‚ɂ‚¢‚Ä‚Ì“Y•t•¶‘‚̉ü’ù.
@“ú–{–òÜŽt‰ïŽGŽ 2015; 67 (12): 1904-1907.
E”Ñ“ˆ‹vŽu. R‚Ä‚ñ‚©‚ñÜCçN•aEçNó‘ÔŽ¡—Í܁C•Ð“ª’ÉŽ¡—ÃÜ ƒoƒ‹ƒvƒŽ_ƒiƒgƒŠƒEƒ€‚Ì”D•wCŽY•wCŽö“û•w“™‚Ö‚Ì“Š
@—^‚ɂ‚¢‚Ä‚Ì“Y•t•¶‘‚̉ü’ù. “ú–{–òÜŽt‰ïŽGŽ 2015; 67 (1): 160-162.
E”Ñ“ˆ‹vŽu. Ž‘±«‘I‘ðH1Žó—e‘̝hREƒAƒŒƒ‹ƒM[«Ž¾Š³Ž¡—ÃÜ ƒƒ‰ƒ^ƒWƒ“‚Ìáz¹‚Ì•›ì—p‚ɂ‚¢‚Ä‚Ì“Y•t•¶‘‚̉ü’ù.
@“ú–{–òÜŽt‰ïŽGŽ 2015; 67 (2): 342-344.
E”Ñ“ˆ‹vŽu. ƒOƒŠƒRƒyƒvƒ`ƒhŒnR¶•¨Ž¿»Ü ƒoƒ“ƒRƒ}ƒCƒVƒ“‰–Ž_‰–‚Ì–òÜ«‰ß•qÇÇŒóŒQ‚Ì•›ì—p‚ɂ‚¢‚Ä‚Ì“Y•t•¶‘
@‚̉ü’ù. “ú–{–òÜŽt‰ïŽGŽ 2015; 67 (9): 1418-1420.
E”Ñ“ˆ‹vŽu. ç—tŒ§‹¤—p”]‘²’†’nˆæˆã—ØAŒgƒpƒX–òÜƒV[ƒg‚̉^—p‚ƍ¡Œã‚Ì“W–].
@ˆã–òƒWƒƒ[ƒiƒ‹ 2014; 50 (7) : 1821-1826.
E”Ñ“ˆ‹vŽu. ç—tŒ§‹¤—p”]‘²’†’nˆæˆã—ØAŒgƒpƒX –òÜƒV[ƒg‚ðŠˆ—p‚µ‚½’nˆæˆã—ØAŒg. ƒpƒXÅ‘Oü 2014; H†: 30-33.
E”Ñ“ˆ‹vŽu. V2-Žó—e‘̝hR–ò ƒgƒ‹ƒoƒvƒ^ƒ“‚ÌŠÌ‹@”\áŠQ‚Ì•›ì—p‚ɂ‚¢‚Ä‚Ì“Y•t•¶‘‚̉ü’ù.
@“ú–òˆã–ò•iî•ñ 2014; 17 (5): 16-18.
E”Ñ“ˆ‹vŽu. Š¿•û»Ü ‰©˜A‰ð“Å“’A‰Á–¡ç–ê¡ŽUAhˆÎ´”x“’‚̏d‘å‚È•›ì—p‚ɂ‚¢‚Ä‚Ì“Y•t•¶‘‚̉ü’ù.
@“ú–òˆã–ò•iî•ñ 2014; 17 (8): 8-10.
E”Ñ“ˆ‹vŽu. Œ|p‚Ƙ_•¶‚Æ—lŽ®”ü. –òŽ–V•ñ 2014; No. 2846: 770.
E”Ñ“ˆ‹vŽu.ç—tŒ§–òÜŽt‰ï–òŽ–î•ñƒZƒ“ƒ^[‚ÌŽæ‚è‘g‚Ý(ã) `’nˆæˆã—Ã’S‚¤–ò‹Ç–òÜŽt‚ðŽx‚¦‚é`.
@PHARMACY NEWSBREAK 2014; 5ŒŽ23“ú.
E”Ñ“ˆ‹vŽu.ç—tŒ§–òÜŽt‰ï–òŽ–î•ñƒZƒ“ƒ^[‚ÌŽæ‚è‘g‚Ý(’†) `Ž¿‚̍‚‚¢Ý‘îˆã—ÂɌü‚¯‚ā`.
@PHARMACY NEWSBREAK 2014; 6ŒŽ12“ú.
E”Ñ“ˆ‹vŽu.ç—tŒ§–òÜŽt‰ï–òŽ–î•ñƒZƒ“ƒ^[‚ÌŽæ‚è‘g‚Ý(‰º) `’²¸EŒ¤‹†‚ƃVƒ“ƒNƒ^ƒ“ƒN`.
@PHARMACY NEWSBREAK 2014; 7ŒŽ10“ú.
E”Ñ“ˆ‹vŽu. ç—tŒ§‹¤—p’nˆæˆã—ØAŒgƒpƒX–òÜƒV[ƒg‚ÌŽ¿“IŒ¤‹†‚ƍ¡Œã‚Ì“W–].
@“ú–{ƒNƒŠƒjƒJƒ‹ƒpƒXŠw‰ïŽ 2014; 16 (1) : 61-64.
E”Ñ“ˆ‹vŽu. ç—tŒ§‹¤—p’nˆæˆã—ØAŒgƒpƒX‚É‚æ‚é–ò–ò˜AŒg –òÜƒV[ƒg‚É‚æ‚éî•ñ‹¤—L.
@“ú–{POSˆã—Êw‰ïŽGŽ 2014; 18 (1) : 58-61.
E”Ñ“ˆ‹vŽu. –òÜŽt‚ªŠÖ‚í‚éˆã—ÃŽ–ŒÌ‚ÌŒ»ó‚Æ‚»‚̑Ήž. ”…ž‰ÈŠw 2014; 40: 32-36.
E”Ñ“ˆ‹vŽu. 5-HT3Žó—e‘̝hRŒ^§“fÜ ƒpƒƒmƒZƒgƒƒ“‰–Ž_‰–‚̏d‘å‚È•›ì—p‚ɂ‚¢‚Ä‚Ì“Y•t•¶‘‰ü’ù. DSU‰ðà.
@“ú–òˆã–ò•iî•ñ 2013; 16 (10): 21-24.
E”Ñ“ˆ‹vŽu. ƒsƒƒŠŒŸ¸‚ð‚·‚®‚ɍs‚í‚È‚¢——R. “úŒoDI. 2013; (6) 045-046.
E”Ñ“ˆ‹vŽu. ƒLƒlƒ_ƒbƒN‚ªH‘O•ž—p‚Å‚ ‚闝—R. “úŒoDI. 2013; (5) 041-042.
E”Ñ“ˆ‹vŽu. ƒNƒ‰ƒoƒ‚ƒbƒNƒX‚𕲂ŗ~‚µ‚¢‚ÆŒ¾‚í‚ꂽ‚ç. “úŒoDI. 2013; (2) PE003-004.
E”Ñ“ˆ‹vŽu. ƒAƒhƒqƒAƒ‰ƒ“ƒXŒüã‚Ì‚½‚߂̈ã—Ïî•ñ‚ÆŒã•ûŽx‰‡.
@‘æ14‰ñ“ú–{ˆã–ò•iî•ñŠw‰ï‘‰ïEŠwp‘å‰ï‹L”OŽ. 2012: 45-47.
E”Ñ“ˆ‹vŽu. ”]‘²’†’nˆæˆã—ØAŒgƒpƒX‚É‚¨‚¯‚é–òÜƒV[ƒg‚̍쐬‚Æ—¯ˆÓ“_.
@ç—tŒ§–òÜŽt‰ïŽGŽ 2012. 58 (6): 443-447.
E‘吟•ü. ‹z“üƒXƒeƒƒCƒh‚ªMDI‚ɕύX‚³‚ꂽ——R. “úŒoDI. 2012; (4) PE001-002.
E”Ñ“ˆ‹vŽu. “®‚«o‚µ‚½u–òÜƒV[ƒgv|–òÜŠÖ˜Aî•ñ‚Ì‹¤—L‰»‚ÉŒü‚¯‚ā|. –òŽ–“ú•ñ.2012. ‘æ11171†.
E”Ñ“ˆ‹vŽu. 2Œ^“œ”A•aŽ¡—Öò ƒGƒLƒZƒiƒ`ƒh. Vˆã–ò•i‚̉ðà. “ú–òˆã–ò•iî•ñ 2012; 15 (4) 17-27.
E”Ñ“ˆ‹vŽu. ç—tŒ§‹¤—p”]‘²’†’nˆæˆã—ØAŒgƒpƒX ‚¢‚æ‚¢‚æŽn‚Ü‚é–òÜƒV[ƒg. –òŽ–“ú•ñ.2012. ‘æ11102†.
E”Ñ“ˆ‹vŽu. R‚Ä‚ñ‚©‚ñÜ ƒŒƒxƒ`ƒ‰ƒZƒ^ƒ€. “ú–òˆã–ò•iî•ñ 2012; 15 (3) 20-51.
E”Ñ“ˆ‹vŽu. ARB‚ÅŽ¡—ÂðŠJŽn‚µ‚½‚ŒŒˆ³Š³ŽÒ. “úŒoDI. 2011; (10) 47-48.
E”Ñ“ˆ‹vŽu. –òÜŽt‚̈ã—ØAŒg‚Ö‚ÌŽQ‰æ. ç—tŒ§–òÜŽt‰ïŽGŽ2011. 57 (7): 467-468.
E”Ñ“ˆ‹vŽu. —Տ°Œ¤‹†‚Ì—Ï—R¸ `–ò‹ÇE•a‰@‚É‚¨‚¯‚éR¸‚Ì•K—v«`. “s–òŽGŽ2011; 33 (4): 15-18.
E”Ñ“ˆ‹vŽu. ‘I‘ð“IDPP-4‘jŠQÜ ƒAƒƒOƒŠƒvƒ`ƒ“ˆÀ‘§Ž_‰–. “ú–òˆã–ò•iî•ñ 2011; 14 (9) 26-44.
E”Ñ“ˆ‹vŽu. ƒqƒgGLP-1ƒAƒiƒƒO’ŽË‰t ƒŠƒ‰ƒOƒ‹ƒ`ƒh. “ú–òˆã–ò•iî•ñ 2011; 14 (5) 28-44.
E”Ñ“ˆ‹vŽu. ŠÌ×–EŠàŽ¡—ÃÜ ƒ~ƒŠƒvƒ‰ƒ`ƒ“…˜a•¨. “ú–òˆã–ò•iî•ñ 2011; 14 (2) 23-42.
E”Ñ“ˆ‹vŽu. –òÜŽt‚ÆŒ¤‹†A–òÜŽt‰ï‚ƃVƒ“ƒNƒ^ƒ“ƒN‹@”\. JAPIC NEWS 2010; 312,8-9.
E”Ñ“ˆ‹vŽu. ’²Ü‚Əî•ñ 2010; 16 (7): 825-827.
E”Ñ“ˆ‹vŽu. –òÜŽt‚̈ã—ØAŒg‚Ö‚ÌŽQ‰æ‚ƍ¡Œã‚Ì“W–]. ç—tŒ§–òÜŽt‰ïŽGŽ2010. 56 (5): 347-351.
E”Ñ“ˆ‹vŽu. ƒmƒ‹ƒAƒhƒŒƒiƒŠƒ“¥ƒZƒƒgƒjƒ“ì“®«R‚¤‚ÂÜ ƒ~ƒ‹ƒ^ƒUƒsƒ“. “ú–òˆã–ò•iî•ñ 2010; 13 (10) 9-38.
E‘吟•ü. šb‘§Ž¡—Âƃtƒ@[ƒ}ƒVƒ…[ƒeƒBƒJƒ‹ƒPƒA. ç—tŒ§–òÜŽt‰ïŽGŽ2009; 55 (7): 547-550.
E”Ñ“ˆ‹vŽu. Rˆ««Žîᇍ܁^ƒ`ƒƒVƒ“ƒLƒi[ƒ[‘jŠQÜ ƒ‰ƒpƒ`ƒjƒuƒgƒVƒ‹Ž_‰–…˜a•¨.
@“ú–òˆã–ò•iî•ñ 2010; 13 (3) 27-43.
E”Ñ“ˆ‹vŽu. ŒoŒû‚»‚¤áyÇ‰ü‘PÜ ƒiƒ‹ƒtƒ‰ƒtƒBƒ“‰–Ž_‰–. “ú–òˆã–ò•iî•ñ 2009; 12 (11) 44-51.
E”Ñ“ˆ‹vŽu. R‘½”­«œ‘ŽîÜ ƒTƒŠƒhƒ}ƒCƒh. “ú–òˆã–ò•iî•ñ 2009; 12 (9) 23-52.
E”Ñ“ˆ‹vŽu. Rˆ««Žîᇍ܁^ƒLƒi[ƒ[‘jŠQÜ ƒXƒjƒ`ƒjƒuƒŠƒ“ƒSŽ_‰–. “ú–òˆã–ò•iî•ñ 2009; 12 (6) 12-52.
E”Ñ“ˆ‹vŽu. RŽ_‹ÛÇŽ¡—Öò ƒŠƒtƒ@ƒuƒ`ƒ“. “ú–òˆã–ò•iî•ñ 2009; 12 (5) 29-44.
E”Ñ“ˆ‹vŽu.ƒTƒŠƒhƒ}ƒCƒh‚̉”\«‚ƈÀ‘SŠÇ—. ç—tŒ§–òÜŽt‰ïŽGŽ2008; 54 (9): 753-756.
E”Ñ“ˆ‹vŽu. R‚Ä‚ñ‚©‚ñÜ ƒgƒsƒ‰ƒ}[ƒg. “ú–òˆã–ò•iî•ñ 2008; 11 (3) 16-44.
E”Ñ“ˆ‹vŽu. ƒzƒXƒzƒWƒGƒXƒeƒ‰[ƒ[5‘jŠQ–ò ƒVƒ‹ƒfƒiƒtƒBƒ‹ƒNƒGƒ“Ž_‰–. “ú–òˆã–ò•iî•ñ 2008; 11 (11) 20-25.
EK“c^ƒ, óˆäGŽ÷, ˆÀ•”Œõº, ”Ñ“ˆ‹vŽu, ˆäŽèŽá“Þ, ŸN“c‘å–ç, ‹v•Û“c—mŽq, ²“¡M”Í, –ΖؔŽ, ã“cŽu˜N, ‚‹´áÁ¶,
@ˆäã’‰•v. ‚¿‚ÎPOS–òÜŒ¤‹†‰ï‚ÌŽæ‚è‘g‚Ý. Pharmacy Today 2007; 20 (1): 2-7.
E”Ñ“ˆ‹vŽu. ‘ãŽÓhR«Rˆ««Žîá‡Ü ƒyƒƒgƒŒƒLƒZƒhƒiƒgƒŠƒEƒ€…˜a•¨. “ú–òˆã–ò•iî•ñ 2007; 10 (8): 41-47.
E”Ñ“ˆ‹vŽu. ˆã–ò•iî•ñ‚ÌŠˆ—p‚ð‚ß‚´‚µ‚Ä. ˆã–ò•iî•ñŠw 2007; 9 (1): 70-71.
E”Ñ“ˆ‹vŽu. Œ’NH•i‚Ì‹qŠÏ“I•]‰¿. ç—tŒ§–òÜŽt‰ïŽGŽ2007; 53(2): 100-107.
E‰Á“¡”ü—R‹I, ”Ñ“ˆ‹vŽu .’˜ìŒ ‚ƈã–ò•iî•ñ. ç—tŒ§–òÜŽt‰ïŽGŽ2007; 53 (6): 465-467.
E”Ñ“ˆ‹vŽu. Šàáu’ÉŽ¡—ÃÜ ƒIƒLƒVƒRƒhƒ“‰–Ž_‰–…˜a•¨. “ú–òˆã–ò•iî•ñ 2007; 10 (6): 30-47.
E”Ñ“ˆ‹vŽu. R¸_•a–ò ƒAƒŠƒsƒvƒ‰ƒ][ƒ‹. “ú–òˆã–ò•iî•ñ 2007; 10 (3): 18-39.
E”Ñ“ˆ‹vŽu. RƒEƒCƒ‹ƒX‰»Šw—Ö@Ü ƒGƒ“ƒeƒJƒrƒ‹…˜a•¨. “ú–òˆã–ò•iî•ñ 2007; 10 (1): 20-40.
E”Ñ“ˆ‹vŽu. ¬’°ƒRƒŒƒXƒeƒ[ƒ‹ƒgƒ‰ƒ“ƒXƒ|[ƒ^[‘jŠQÜ ‚Ž‰ŒŒÇŽ¡—ÃÜ ƒGƒ[ƒ`ƒ~ƒu.
@“ú–òˆã–ò•iî•ñ 2007; 10 (12) 8-27.
E”Ñ“ˆ‹vŽu. ”ñƒXƒeƒƒCƒh«Á‰ŠE’Á’ÉÜ (COX-2‘I‘ð“I‘jŠQÜ) ƒZƒŒƒRƒLƒVƒu.
@“ú–òˆã–ò•iî•ñ 2007; 10 (10) 17-45.
E”Ñ“ˆ‹vŽu. ƒWƒFƒlƒŠƒbƒNˆã–ò•i‚Ì•]‰¿‚ÆŒoÏ«. ç—tŒ§–òÜŽt‰ïŽGŽ2006; 52 (3): 217-233.
E”Ñ“ˆ‹vŽu. ˆã—Ë@ŠÖ‚É‚¨‚¯‚éˆã–ò•iî•ñŒ¹‚ÌŒ»ó. JAPIC J. 2006; 7: 109-123.
E”Ñ“ˆ‹vŽu. ‘I‘ð“IƒZƒƒgƒjƒ“ÄŽæ‚荞‚Ý‘jŠQÜ ‰–Ž_ƒZƒ‹ƒgƒ‰ƒŠƒ“. “ú–òˆã–ò•iî•ñ2006; 9 (10): 26-48.
E”Ñ“ˆ‹vŽu. RŒŒ¬”ÂÜ —°Ž_ƒNƒƒsƒhƒOƒŒƒ‹. “ú–òˆã–ò•iî•ñ 2006; 9 (8): 15-32.
E”Ñ“ˆ‹vŽu.@“œ”A•aHŒã‰ßŒŒ“œ‰ü‘PÜ ƒ~ƒOƒŠƒg[ƒ‹. “ú–òˆã–ò•iî•ñ 2006; 9 (2): 28-40.
E”Ñ“ˆ‹vŽu. ƒWƒFƒlƒŠƒbƒNˆã–ò•i‚É“àÝ‚·‚郁ƒŠƒbƒgEƒfƒƒŠƒbƒg. –ò‚Ì’mŽ¯ 2005; 56 (4): 70-73.
E”Ñ“ˆ‹vŽu.@”x“®–¬«‚ŒŒˆ³ÇŽ¡—ÃÜ ƒ{ƒZƒ“ƒ^ƒ“…˜a•¨. “ú–òˆã–ò•iî•ñ 2005; 8 (9): 20-32.
E”Ñ“ˆ‹vŽu.@RƒEƒCƒ‹ƒX‰»Šw—Ö@Ü ƒAƒfƒzƒrƒ‹ƒsƒ{ƒLƒVƒ‹. “ú–òˆã–ò•iî•ñ 2005; 8 (7): 23-40.
E”Ñ“ˆ‹vŽu. ƒWƒFƒlƒŠƒbƒNˆã–ò•i‚̏î•ñ•]‰¿. ŒŽŠ§ƒWƒFƒlƒŠƒbƒN 2004; 13: 33-36.
E”Ñ“ˆ‹vŽu. ‚±‚ê‚©‚ç‚ÌOTC–ò. ˆã–ò•iî•ñŠw 2004; 5 (4): 198-199.
E”Ñ“ˆ‹vŽu. ˆã—Ïî•ñ‹Zp‚̐i•à‚ƌlî•ñ•ÛŒì–@. ç—tŒ§–òÜŽt‰ïŽGŽ2004; 50 (1): 31-34.
E”Ñ“ˆ‹vŽu. “Œ—mˆãŠw‚É‚¨‚¯‚鍂ŒŒˆ³Ž¡—Ã. ç—tŒ§–òÜŽt‰ïŽGŽ2004; 50 (6): 430-433.
Eç—tŒ§–òÜŽt‰ï–òŽ–î•ñƒZƒ“ƒ^[. ˆã–ò•iî•ñQ&A. “ú–{–òÜŽt‰ïŽGŽ 2004; 56 (3), 77.
E”Ñ“ˆ‹vŽu. ƒWƒFƒlƒŠƒbƒNˆã–ò•i‚É‚¨‚¯‚éî•ñ‚̉¿’l•]‰¿. ˆã–ò•iî•ñŠw 2003; 5 (2): 79-82.

EWIBA 2001”N”Å, K“c³F, ‚‹vŽj–›, ’؈ä‰hF, ŽO•¶•v (‘ŠÄC), “Œ‹ž, “ú–{ˆã—Êé‰æ, 2001.